Key Takeaways
- COAST-AF,run at14Canadian centres,tested if adding ablation of low-voltage (scarred) atrial tissue to the standard pulmonary vein isolation procedure lowers atrial fibrillation.
- Overall it did not:recurrence was 49.4% with the added ablation versus 57.5% without,a difference that was not statistically significant -so routine extra ablation for all patients
- In the pre-planned subgroup of 268 patients whose hearts actually showed low-voltage areas,recurrence was clearly lower with the added treatment,49.3%versus 69.2%-a finding theory.
More Burning Was Supposed to Mean Less Fibrillation
For persistent atrial fibrillation, the standard catheter ablation — pulmonary vein isolation — works only about half the time, so specialists have long added extra ablation on visibly scarred, low-voltage patches of atrial tissue, reasoning that the scar is where the chaos lives. COAST-AF, a Canadian trial published November 8 in JAMA, finally tested that instinct head-on: 508 patients with persistent AF, treated at 14 Canadian centres, randomized to standard isolation alone or isolation plus low-voltage-area ablation.
The Honest Headline: It Did Not Work — for Everyone
After an average of 21 months, AF came back in 49.4% of the extra-ablation group versus 57.5% of the standard group. That gap looks promising on a poster; statistically it is not significant (hazard ratio 0.82, P = .11), which means chance cannot be ruled out. The procedures took longer with the added ablation, and safety was similar. The authors' bottom line is plain: routinely adding low-voltage ablation for every persistent-AF patient is not supported.
But the trial was designed with a second question. In the pre-specified subgroup of 268 patients whose mapping actually found low-voltage areas — the very tissue the extra ablation targets — recurrence was 49.3% with added ablation versus 69.2% without, and the benefit held across the follow-up analyses. That is a subgroup inside an overall neutral trial, so it is a strong lead, not proof: the researchers themselves say it needs a confirmatory trial, and intermittent rhythm monitoring may have missed some silent recurrences.
The Twikup Take
A negative trial that tells you exactly who might benefit is worth more than a positive trial that tells you nothing. COAST-AF's real result is a targeting lesson: treat the scar when there is a scar — and stop charging everyone else the longer procedure.
Image: Illustrative image.